Wall Street analysts predict that Zafgen Inc (NASDAQ:ZFGN) will report earnings of ($0.40) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Zafgen’s earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.44). Zafgen posted earnings per share of ($0.58) in the same quarter last year, which indicates a positive year-over-year growth rate of 31%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Zafgen will report full-year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.93) to ($1.31). For the next fiscal year, analysts expect that the company will report earnings of ($1.71) per share, with EPS estimates ranging from ($2.34) to ($1.15). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Zafgen.

Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.04.

ZFGN has been the subject of several analyst reports. JMP Securities raised their price target on Zafgen from $8.00 to $17.00 and gave the company a “hold” rating in a report on Tuesday, March 12th. They noted that the move was a valuation call. Cowen restated a “hold” rating on shares of Zafgen in a report on Thursday, January 17th. Leerink Swann upgraded Zafgen from a “market perform” rating to an “outperform” rating and set a $4.52 price target for the company in a report on Thursday, February 7th. Piper Jaffray Companies reduced their price target on Zafgen from $18.00 to $6.00 and set a “hold” rating for the company in a report on Monday, March 11th. Finally, Svb Leerink upgraded Zafgen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $9.45.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wedbush Securities Inc. bought a new stake in Zafgen in the 1st quarter worth about $96,000. Geode Capital Management LLC increased its holdings in Zafgen by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 420,983 shares of the biopharmaceutical company’s stock worth $2,083,000 after buying an additional 22,235 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Zafgen by 2.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 904,194 shares of the biopharmaceutical company’s stock worth $4,476,000 after buying an additional 21,423 shares in the last quarter. 683 Capital Management LLC increased its holdings in Zafgen by 7.7% in the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the biopharmaceutical company’s stock worth $6,930,000 after buying an additional 100,000 shares in the last quarter. Finally, Great Point Partners LLC increased its holdings in Zafgen by 6.1% in the 4th quarter. Great Point Partners LLC now owns 3,598,392 shares of the biopharmaceutical company’s stock worth $17,812,000 after buying an additional 207,007 shares in the last quarter. Institutional investors own 86.74% of the company’s stock.

Shares of NASDAQ:ZFGN opened at $2.59 on Friday. Zafgen has a 1-year low of $2.57 and a 1-year high of $12.35. The company has a quick ratio of 9.12, a current ratio of 9.12 and a debt-to-equity ratio of 0.16. The firm has a market cap of $96.65 million, a PE ratio of -1.36 and a beta of -0.42.

About Zafgen

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

See Also: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.